Drugs / XC8
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05294250 | Feb 2022 | — | Valenta Pharm JSC | Completed | No outcome recorded |
| Phase 1 | NCT03441815 | Feb → Jul 2015 | asthma | PHARMENTERPRISES LLC | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT05269329 | Apr → Oct 2021 | common cold, influenza | Valenta Pharm JSC | Completed | No outcome recorded |
| Phase 2 | NCT04674137 | Dec 2020 → Aug 2021 | T2-high asthma | Chemlmmune Therapeutics LLC | Completed | No outcome recorded |
| Phase 2 | NCT03450434 | Sep 2016 → Sep 2017 | asthma | PHARMENTERPRISES LLC | Completed | Missed primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03441373 | Feb 2016 → Feb 2017 | influenza | PHARMENTERPRISES LLC | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06379542 | Dec 2023 → Dec 2025 | viral respiratory tract infection | Valenta Pharm JSC | Unknown | No outcome recorded |
| Phase 3 | NCT05273619 | May → Jul 2022 | common cold, influenza | Valenta Pharm JSC | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02882217 Comparator | Aug 2016 → May 2017 | asthma | EURRUS Biotech GmbH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XC8 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06379542 ↗ |
| Known as | histamine glutarimide | “XC8 (histamine glutarimide) is a novel agent” PMID 31597083 ↗ Oct 2019 |
| Route | Oral | “safety of oral XC8” PMID 31597083 ↗ Oct 2019 |